ARCT - Moderna BioNTech slide as CDC sees a likely association of heart inflammation and COVID-19 vaccines

carmengabriela/iStock Editorial via Getty Images The manufacturers of messenger-RNA-based COVID-19 vaccines are trading lower after a safety group of the U.S. Centers for Disease Control and Prevention ((CDC)) said there is a “likely association” between a rare heart inflammation following the second dose of mRNA-based COVID-19 shots. Over 1,200 cases of myocarditis or pericarditis were reported in those aged between 16 and 24 years who received COVID-19 vaccines developed by Pfizer ([[PFE]] -1.1%)/BioNTech ([[BNTX]] -5.3%) and Moderna ([[MRNA]] -6.7%), CNBC reported quoting data from the CDC. Approximately 300M vaccine doses have been administered as of June 11. Most of the cases were mild and occurred in those aged below 30, according to the presentation published for Wednesday’s meeting of the CDC’s Advisory Committee on Immunization Practices. Out of 295 cases, 79% of those who were affected made a full recovery while nine were hospitalized with two requiring intensive care treatment. “Clinical presentation of

For further details see:

Moderna, BioNTech slide as CDC sees a “likely association” of heart inflammation and COVID-19 vaccines